相关实验视频

Updated: May 28, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

设计强效EGFR-TK抑制剂的综合计算方法:QSAR,对接,ADMET和分子动力学研究

Shital M Patil¹, Kalyani Asgaonkar¹, Shashikant Bhandari¹

¹Department of Chemistry, AISSMS College of Pharmacy, Pune, Maharashtra, India.

Chemistry & biodiversity

|February 12, 2025

概括

研究人员使用QSAR和分子建模开发了一种新的EGFR抑制剂. NCE 2是一种 thiazolyl-pyrazoline衍生物,显示出强大的EGFR抑制和有利的药物特性,提供了一个有前途的新癌症治疗候选人.

科学领域:

药用化学医学化学
计算化学计算化学
癌症治疗方法癌症治疗方法

背景情况:

表皮生长因子受体 (EGFR) 是癌症治疗的关键标.
现有的EGFR氨酸激酶抑制剂 (TKI) 面临药物耐药性和毒性方面的挑战.
要克服这些局限性,需要优化药和新型化学实体 (NCE).

研究的目的:

开发一个3D定量结构-活性关系 (QSAR) 模型,以优化EGFR抑制剂药.
设计和评估具有改进抗癌特性的新型化学实体 (NCE).
评估设计的NCE与EGFR的药物相似性,稳定性和结合 afinity.

主要方法:

在施罗丁格Maestro v13.4.4 中使用42个 thiazolyl-pyrazoline 衍生物构建了 QSAR 模型.
使用QikProp.进行了吸收,分布,新陈代谢,分泌和毒性 (ADMET) 分析.
使用Desmond进行了分子对接和100 ns分子动力学模拟,以评估结合稳定性和相互作用.

主要成果:

建立了一个显著的QSAR模型 (R2 = 0.7880,Q2 = 0.7341).
确定了40种具有良好的类似药物特性的NCE.
NCE 2 呈现出高的对接得分 (-8.178 kcal/mol) 和与EGFR结合部位 (RMSD 2.42.8 Å) 的稳定相互作用.

结论:

NCE 2是一种新型的 thiazolyl-pyrazoline 衍生物,显示出显著的EGFR 抑制活性.
该化合物具有有利的ADMET特性和结构稳定性.
作为一种抗癌剂,NCE 2 是进一步临床前开发的有希望的候选药物.

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...